COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC:
Get the latest research information from NIH:

Coronavirus Guidance for NIH Applicants and Grantees:

Dr. Malaya Chatterjee

Dr. Malaya Chatterjee

Scientific Review Officer


Division of Translational and Clinical Sciences DTCS
Oncology 2 – Translational Clinical OTC
Study Section:
Clinical Oncology CONC

Malaya Chatterjee, Ph.D. is the Scientific Review Officer for CSR’s Clinical Oncology Study Section. Before coming to CSR, she was a tenured full professor in the Department of Internal Medicine at both the University of Cincinnati and the University of Kentucky. Her major research interests are tumor immunology and immunotherapy of cancer with tumor vaccines. She has published extensively, including 119 manuscripts in peer-reviewed journals.

Dr. Chatterjee also was invited to write several review articles and book chapters. She holds ten United States Patents on anti-idioypic vaccines for colon cancer, melanoma and breast cancer. Phase I/II clinical trials were conducted with many of these vaccines. She has trained several graduate students pursuing Ph.D.s and also trained post-doctoral fellows. She was a chartered member of three NIH Study Sections and also served as a temporary reviewer on the Cancer Immunopathology and Immunotherapy Study Section, program project grants site visits, and Department of Defense (DOD) Study Sections. Grants from the NIH and DOD supported Dr. Chatterjee’s research.